Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study by Aleil, Boris et al.
C
R
P
R
R
B
M
J
J
S
O
g
d
B
r
M
d
s
r
R
i
o
i
7
d
b
C
m
l
s
E
C
F
F
M
I
R
a
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 , N O . 6 , 2 0 0 8
© 2 0 0 8 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 8 / $ 3 4 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 8 . 0 9 . 0 0 4lopidogrel 150 mg/day to Overcome Low
esponsiveness in Patients Undergoing Elective
ercutaneous Coronary Intervention
esults From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02)
andomized Study
oris Aleil, MD, PHD,*† Laurent Jacquemin, MD,‡ Fabien De Poli, MD,§
ichel Zaehringer, MD,† Jean-Philippe Collet, MD PHD, Gilles Montalescot, MD, PHD,
ean-Pierre Cazenave, MD, PHD,* Marie-Claude Dickele, MD,§
ean-Pierre Monassier, MD, FESC,‡ Christian Gachet, MD, PHD*
trasbourg, Mulhouse, Haguenau, and Paris, France
bjectives We investigated whether maintenance therapy with clopidogrel 150 mg/day produces
reater platelet inhibition than the standard 75-mg/day dose and whether the higher maintenance
ose increases platelet inhibition in low responders to clopidogrel 75 mg/day.
ackground Patients show interindividual variability in their platelet response to clopidogrel. Low
esponders could potentially obtain greater clinical beneﬁt from greater doses of clopidogrel.
ethods One hundred ﬁfty-three elective percutaneous coronary intervention patients were ran-
omized to clopidogrel 150 mg/day (n  58) or 75 mg/day (n  95) for 4 weeks, with vasodilator-
timulated phosphoprotein assay-guided switching to clopidogrel 150 mg/day after 2 weeks in low
esponders (platelet reactivity index 69%). All patients received aspirin 75 mg/day.
esults After 2 weeks, clopidogrel 150 mg/day produced a signiﬁcantly lower platelet reactivity
ndex than clopidogrel 75 mg/day (43.9  17.3% vs. 58.6  17.7%; p  0.0001). The proportion
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n those randomized to clopidogrel 75 mg/day (8.6% vs. 33.7%; p  0.0004). In the clopidogrel
5 mg/day group, 64.5% (20 of 31) of low responders became responders after switching to clopi-
ogrel 150 mg/day for 2 weeks. No major bleeds occurred during the study; the incidence of minor
leeds was similar in each treatment group.
onclusions In elective percutaneous coronary intervention patients, a 150-mg/day clopidogrel
aintenance dose produces greater inhibition of platelet function than clopidogrel 75 mg/day. In
ow responders to clopidogrel 75 mg/day, switching to clopidogrel 150 mg/day overcomes low re-
ponsiveness in a majority of patients. These ﬁndings warrant further clinical evaluation. (VASP-02;
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632lopidogrel in association with aspirin is currently the
eference antiplatelet strategy to prevent the thrombotic
omplications of percutaneous coronary intervention (PCI)
ith stenting (1). Clopidogrel is a thienopyridine com-
ound that, after hepatic metabolization, inhibits adenosine
iphosphate (ADP)-induced platelet aggregation by specific
nd irreversible blockade of the platelet P2Y12 receptor
2,3). It exerts a dose-dependent inhibition of platelet
ggregation and prolongation of the bleeding time (4,5).
uring the 1990s, the maintenance dose of 75 mg daily was
nitially chosen because its biological effects were similar to
hose of ticlopidine 250 mg twice daily. A greater mainte-
ance dose of clopidogrel was not selected for safety reasons,
ostly the fear of an increased bleeding risk (4,5). However,
wide interindividual variability of clopidogrel responsive-
ess has been observed (6–8), and patients exhibiting low
esponse to clopidogrel are at risk for worsened cardiovas-
ular outcomes (9,10).
The mechanisms of this inter-
individual variability to clopi-
dogrel responsiveness are not yet
completely resolved but are the
result of poor compliance (11),
variable metabolization of the
pro-drug in the liver (12,13), in-
trinsic high platelet reactivity (6),
variable intestinal absorption (14),
or possible drug–drug interactions
(15–18). Therefore, to improve
clinical outcome, faster onset of
action and better inhibition of
platelet function are required,
which can be achieved by the use
of increased loading doses of clo-
pidogrel (19–21). In parallel, pra-
sugrel, a more potent thienopyri-
ine compound, demonstrates greater inhibition of platelet
ggregation and a lower proportion of biological nonre-
ponders compared with the standard doses of clopidogrel (22).
n addition, TRITON–TIMI-38 (Trial to Assess Improve-
ent in Therapeutic Outcomes by Optimizing Platelet Inhi-
ition with Prasugrel–Thrombolysis In Myocardial Infarction-
8) clearly demonstrated the clinical benefit of inhibiting
latelet function more strongly in the setting of PCI; however,
ncreased bleeding, including fatal bleeding, was observed (23).
Although the authors of several studies have demon-
trated the advantage of greater loading doses in PCI
19–21), the question of the chronic maintenance dose of
lopidogrel after PCI is less well addressed. Thus, 4 studies
ave shown a greater platelet inhibition with 150 mg/day of
lopidogrel compared with 75 mg/day. These data were
btained in studies with a small sample size or in diabetic
atients (24–27). The primary objectives of our study were:
bbreviations
nd Acronyms
DP  adenosine
iphosphate
I  confidence interval
FI  mean fluorescence
ntensity
R  odds ratio
CI  percutaneous
oronary intervention
GE1  prostaglandin E1
PI  proton-pump inhibitor
RI  platelet reactivity
ndex
ASP  vasodilator-
timulated phosphoprotein) to compare the biological effects of 150 mg/day versus 75 mg/day clopidogrel in patients undergoing elective PCI;
nd 2) to assess, in patients defined as nonresponders to the
pproved 75 mg/day maintenance dose of clopidogrel,
hether doubling the dose would result in improved bio-
ogical parameters. To define the biological responsiveness
o clopidogrel, we used the vasodilator-stimulated phospho-
rotein (VASP) phosphorylation assay because it is a selec-
ive biochemical marker of the P2Y12 receptor activation
28) instead of a global platelet function test, such as light
ransmission aggregometry, which might be influenced by
any factors.
ethods
atients. Patients were enrolled between April 2005 and
ecember 2007 in this open, randomized, multicenter
linical trial. They were patients age 18 years scheduled
or elective coronary stenting. Exclusion criteria were as
ollows: acute coronary syndrome, thienopyridine use before
he enrollment, contraindication to clopidogrel or aspirin
reatment, or the presence of a disease requiring chronic
nticoagulant therapy. The study protocol was approved by
he institutional ethics committee, and all patients gave
ritten informed consent for participation.
lood sampling. Samples were obtained before clopidogrel
dministration, between 10 and 12 h after the clopidogrel
oading dose and at 2 and 4 weeks after the start of the
aintenance dose of clopidogrel (Fig. 1). Whole blood was
ollected into 0.129 mol/l sodium citrated 4.5-ml tubes (BD
acutainer, Becton Dickinson, Plymouth, United King-
om) for VASP assay and into 1 K3E BD Vacutainer 3-ml
ube (Becton Dickinson) for blood cell counts. Citrated
lood samples were shipped by road transport to the central
aboratory (EFS-Alsace, Strasbourg, France), where analy-
es of platelet VASP phosphorylation were performed
ithin 36 h after blood sampling. This organization was
easible because of the high temporal stability (48 h) during
ransport and storage at room temperature of citrated blood
amples for quantitative flow cytometric analysis of VASP
hosphorylation (29).
low cytometry. Platelet VASP phosphorylation state was
etermined by quantitative flow cytometry with the Platelet
ASP assay and following the instructions of the manufac-
urer (Diagnostica Stago/Biocytex, Asnières, France). This
ethod has been previously described and used to monitor
he platelet inhibition by thienopyridines (7,28,30–33). In
rief, citrated whole blood was incubated with prostaglan-
in E1(PGE1) or PGE1 and ADP for 10 min and fixed with
araformaldehyde, after which the platelets were permeab-
lized with nonionic detergent. The cells were labeled with
primary monoclonal antibody against serine 239-
hosphorylated VASP (16C2), followed by a secondary
uorescein isothiocyanate-conjugated polyclonal goat anti-
ouse antibody. The platelet population was identified with
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633n anti-CD61 phycoerythrin-labeled antibody. Analyses
ere performed on a Becton Dickinson FACS Calibur
pectrometer at a medium rate, and 10,000 platelets were
ated. A platelet reactivity index (PRI) was calculated from
he mean fluorescence intensity (MFI) of samples incubated
ith PGE1 or PGE1 and ADP according to the formula:
RI  [(MFI(PGE1)  MFI(PGE1ADP))/MFI(PGE1)]  100
tudy protocol. The study protocol is shown in Figure 1.
fter enrollment, the day before the coronary stenting
rocedure, patients received a loading dose of clopidogrel
300 to 600 mg at the physician’s discretion) and were then
andomly assigned to receive 75 (1 tablet) or 150 mg (2
ablets) once-daily clopidogrel for 2 weeks. The randomiza-
ion sequence was provided by the central laboratory. We
andomized patients in a ratio of 3:2 for clopidogrel 75 mg
ersus clopidogrel 150 mg using a 30% projected rate of
onresponders with the clopidogrel 75-mg dose, on the
asis of our previous study (30). In addition to the random-
zed study medication, each patient received 75 mg/day of
spirin.
As we reported previously, patients with a PRI 69%
ere considered as low responders to clopidogrel (30). The
hreshold of 69% was chosen on the basis of the results of
ur previous study, in which we found that approximately
0% of the patients receiving clopidogrel treatment were
ndistinguishable from untreated patients, the value of 69%
orresponding to the mean minus 2 SDs (30). After the first
weeks of treatment, the VASP assay was performed, and
he daily doses of clopidogrel (75 or 150 mg) were main-
inclusion
in the study and
centralized
randomization
loading dose
of
clopidogrel
(300 to 600 mg) PCI
clopidogrel
clopidogrel
VASP
analysis
2 week
10-12 h
VASP
analysis
Figure 1. Design of the VASP-02 Study
Flow Chart of the Study. PCI  percutaneous coronary intervention; PRI  plaained for each patient for the 2 next weeks, except for 1atients who had a high PRI (69%) and were declared low
esponders to clopidogrel 75 mg/day. In these patients, the
aily dose of clopidogrel was switched from 75 to 150 mg
or the 2 next weeks, after which the VASP assay was
erformed again. Compliance with clopidogrel treatment
as checked by counting the tablets of clopidogrel remain-
ng in the blister packs at each visit.
ollow-up. A clinical follow-up was established at 2 and 4
eeks after the PCI. Ischemic events were defined as death
econdary to any cardiovascular cause, stroke, myocardial
nfarction, documented ischemia requiring target-vessel re-
ascularization, or improvement of medical treatment. Mi-
or bleeding corresponded to the increase of skin bleeding
after shaving for example), appearance of epistaxis, or gum
leeding about which the patient complains. Major bleeding
as defined as intracranial bleeding or any decrease in
emoglobin requiring a transfusion.
tatistical analyses. Results are expressed as the mean 
D. For univariate analysis, qualitative data were analyzed
ith a bilateral Fisher exact test. Nonparametrical tests were
sed to compare continuous values between groups (Mann-
hitney or Kruskal-Wallis tests, depending on the number
f groups; Wilcoxon rank sum test for paired tests). Con-
inuous variables were further dichotomized (with the me-
ian as cutoff value) for subsequent logistic regression to
redict a high or a low value of PRI, on the basis of age,
ender, body weight, platelet count, cardiovascular risk
actors, history of coronary artery disease, clopidogrel treat-
ent, and concomitant medications. All significance levels
ere set at 0.05. Computations were performed with SPSS
/day
g/day
2 weeks
VASP
analysis
VASP
analysis
clopidogrel 75 mg/day
clopidogrel 150 mg/day
"responder" patients to
clopidogrel 75 mg/day (PRI < 69%)
"non responder" patients to
clopidogrel 75 mg/day (PRI ≥ 69%)
eactivity index; VASP  vasodilator-stimulated phosphoprotein.75 mg
150 m
s4.0 (SPSS Inc., Chicago, Illinois).
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634esults
he characteristics of the study population after random-
zation are shown in Table 1. No difference was observed
etween the study groups. The PRI values before clopi-
ogrel were 86.2  4.7% for the 75-mg/day group and 86.1
4.0% for the 150-mg/day group (p 0.72). After 2 weeks
f clopidogrel treatment (mean 15.2  2.5 days), the PRIs
ere decreased and significantly lower in patients receiving
lopidogrel 150 mg/day compared with those receiving
5 mg/day (43.9  17.3% vs. 58.6  17.7%; p  0.0001)
Fig. 2).
The mean relative reduction of PRI from the baseline
alue measured before the loading dose was 32% with
lopidogrel 75 mg/day and 49% with clopidogrel 150
g/day (p  0.0001). Strikingly, the range of the interin-
ividual variability of the response to clopidogrel remained
Table 1. Baseline Characteristics of Patients According to the
Clopidogrel Maintenance Dose
Clopidogrel
75 mg/day 150 mg/day p
Value(n  95) (n  58)
Age, yrs 64.3 9.7 65.9 9.7 0.28
Male gender 77 (81) 49 (84) 0.59
Weight, kg 83.6 13.5 83.7 12.4 0.78
Current smoking 17 (18) 7 (12) 0.34
Hypercholesterolemia 58 (61) 42 (72) 0.15
Arterial hypertension 65 (68) 32 (55) 0.10
Diabetes mellitus 23 (24) 14 (24) 0.99
Previous MI 11 (12) 6 (10) 0.81
Previous PTCA 11 (12) 12 (21) 0.11
Previous CABG 5 (5) 6 (10) 0.24
Concomitant medications
Beta-blocker 66 (69) 41 (71) 0.87
ACE inhibitor 31 (33) 16 (28) 0.51
AII-R blocker 23 (24) 15 (26) 0.82
Statin 73 (77) 47 (81) 0.54
Proton-pump inhibitor 24 (26) 17 (29) 0.61
Procedural variables
LAD 50 (53) 24 (41) 0.18
Cx 24 (25) 16 (28) 0.75
RCA 29 (31) 27 (47) 0.05
1 BMS implantation 40 (42) 23 (40) 0.77
1 DES implantation 56 (59) 37 (64) 0.55
GP IIb/IIIa inhibitor 5 (5) 1 (2) 0.19
Platelet count (103/l) 256 74 52 69 0.58
Leukocyte count (103/l) 7.2 2.0 7.3 2.2 0.89
Red cell count (103/l) 4.5 0.4 4.6 0.4 0.06
Values are mean SD or n (%).
AII-R  angiotensin II receptor; ACE  angiotensin-converting enzyme; BMS  bare-metal
stent; CABG coronary artery bypass grafting; Cx circumflex artery; DES drug-eluting stent;
GP  glycoprotein; LAD  left anterior descending artery; MI  myocardial infarction; PTCA percutaneous transluminal coronary angioplasty; RCA right coronary artery.ide at 150 mg/day (from 3% to 77%) as it is at 75 mg/day
from 7% to 88%). However, the proportion of low re-
ponders (according to the threshold of 69%) was substan-
ially lower with clopidogrel 150 mg/day than with 75
g/day (5 of 58 [8.6%] vs. 32 of 95 [33.7%], respectively;
 0.0004). Multivariate analysis (Table 2) showed the
ignificant effect of the greater maintenance dose of clopi-
ogrel on the PRI at 2 weeks (odds ratio [OR]: 0.140, 95%
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Figure 2. Platelet Reactivity Index at 2 Weeks According to the
Maintenance Dose of Clopidogrel
The horizontal broken line represents the threshold of 69% used to
deﬁne the low-responder patients (see text for details).
Table 2. Determinants of Platelet Reactivity Index (VASP Method)
2 Weeks After the Initiation of the Clopidogrel Treatment
(Logistic Regression)
Variable OR 95% CI p Value
Age (65 yrs) 0.511 0.190–1.377 0.184
Gender (male) 0.503 0.146–1.736 0.277
Weight (83 kg) 2.710 1.140–6.443 0.024
Current smoking 0.567 0.164–1.957 0.369
Hypercholesterolemia 1.282 0.512–3.213 0.596
Arterial hypertension 1.856 0.657–5.242 0.243
Diabetes mellitus 0.646 0.428–3.925 0.646
History of CAD 0.637 0.210–1.931 0.425
Clopidogrel loading dose 0.944 0.575–1.549 0.819
Clopidogrel maintenance dose (150 mg/day) 0.140 0.055–0.358  0.0001
ACE inhibitor 1.711 0.605–4.841 0.311
AII-R blocker 1.311 0.432–3.977 0.632
Statin 0.923 0.340–2.504 0.875
Proton-pump inhibitor 2.546 0.960–6.753 0.060
Platelet count (243,000 platelets/l) 0.829 0.338–2.034 0.683
CAD coronary artery disease; CI confidence interval; OR odds ratio; VASP vasodilator-stimulated phosphoprotein; other abbreviations as in Table 1.
c
G
g
0
o
i
p
d
m
5
o
t
f
O
a
1
(
r
w
v
b
8
o
d
P
2
0
i
e
w
m
N
r
s
t
l
l
t
o
c
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 6 , 2 0 0 8
D E C E M B E R 2 0 0 8 : 6 3 1 – 8
Aleil et al.
Doubling Clopidogrel Maintenance Dose
635onfidence interval [CI]: 0.055 to 0.358; p  0.0001).
reater body weight was also significantly associated with
reater PRI (OR: 2.710, 95% CI: 1.140 to 6.443; p 
.024), whereas a similar but nonsignificant trend was
bserved with concomitant medication with proton-pump
nhibitors (PPIs) (OR: 2.546, 95% CI: 0.960 to 6.753;
 0.060).
Thirty-two patients receiving clopidogrel 75 mg/day were
eclared low responders. At 2 weeks, most of them had a
odest decrease of the PRI (from 85.4  4.6% to 76.2 
.0%; p  0.0001) (Fig. 3) without reaching the threshold
f 69%. In 31 of these patients, the increase in the daily dose
o 150 mg/day resulted in a further decrease of the PRI,
rom 76.2  5.0% to 61.5  12.3% (p  0.0001) (Fig. 3).
ne patient did not comply with the protocol, which led to
n increase in PRI after being asked to switch from 75 to
50 mg. The PRI values in this patient were high at 2
73.5%) and at 4 weeks (73.0%). Thus, 20 of the 31 low
esponders (64.5%) became responders to clopidogrel,
hereas 11 (35.5%) remained low responders. The PRI
alues before clopidogrel administration were no different
etween responders and low responders (86.7  4.7% vs.
5.4  4.6%, respectively; p  0.17).
Interestingly, in the 118 patients receiving clopidogrel 75
r 150 mg/day and in whom the clopidogrel maintenance
ose was not modified during the month of the study, the
RI was found to be remarkably stable between the visits at
weeks and at 4 weeks (intraclass correlation coefficient 
.893, 95% CI: 0.846 to 0.926; p  0.0001) (Fig. 4).
The clinical events during 1-month follow-up are shown
n Table 3. Only 1 patient presented a documented ischemic
vent requiring the improvement of medical treatment
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Figure 3. Effect of Increasing the Maintenance Dose of Clopidogrel From
75 to 150 mg/day in Low Responders to 75 mg/day (n  31)
The horizontal broken line represents the threshold of 69% used to
deﬁne the low-responder patients (see text for details).ithout new PCI. This patient was assigned to receive 75
g/day and was a nonresponder to this dose (PRI: 73.5%).
o fatal cardiovascular events or major bleedings were
ecorded during the 1-month follow-up. There was no
ignificant difference in the rate of minor bleedings between
he 75- and 150-mg groups.
The PRI measured 10 to 12 h after the clopidogrel
oading dose correlated well with PRI at 2 weeks, when the
oading dose was 600 mg but not 300 mg. It suggests that
he PRI at 10 to 12 h after a 600-mg load could predict the
verall responsiveness of the patient, including during
hronic therapy (Table 4).
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Figure 4. Stability of the Clopidogrel Effect at Constant
Maintenance Dose
Stability of the clopidogrel effect on the platelet reactivity index (PRI)
between the visits at 2 weeks and at 4 weeks in patients whose clopi-
dogrel maintenance dose (75 mg/day [open circles]; n  62 and 150
mg/day [closed circles]; n  56) was not modiﬁed. The broken line repre-
sents theoretical equality between PRI values at 2 weeks and 4 weeks.
Table 3. One-Month Clinical Follow-Up
Clopidogrel
p
Value
75 mg/day
(n  62)
150 mg/day
(n  58)
75–150 mg/day
(n  31)
Ischemic event 1 (1.6) 0 (0) 0 (0) 0.486
Cardiovascular death 0 (0) 0 (0) 0 (0) —
Minor bleed 14 (22.6) 11 (19.0) 3 (9.7) 0.318
Major bleed 0 (0) 0 (0) 0 (0) —Values are n (%).
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636iscussion
he 2 major results of this study are: 1) the confirmation
hat a stronger inhibition of platelet activation is measured
hen clopidogrel is administered at 150 mg/day compared
ith the recommended maintenance dose of 75 mg/day;
nd 2) that increasing the dose of clopidogrel to 150 mg/day
n individuals detected as low responders improved the
iological outcome, as evaluated with the P2Y12-selective
ASP phosphorylation test (30,34). The greater inhibition
f platelet activation obtained by clopidogrel 150 mg/day
ompared with the standard dose of 75 mg/day is in line
ith the results described by von Beckerath et al. (24) and
ngiolillo et al. (35) in post-PCI and Angiolillo et al. (25)
n diabetic patients using conventional aggregometry or the
erifyNow P2Y12 assay (Accumetrix, San Diego, Califor-
ia).
Overall, these results are not surprising, considering the
ose-dependent nature of the inhibition exerted by the
hienopyridine compounds on platelet functions either as a
oading dose or under chronic treatment (4,5,19 –22,
6–38). Thus, several studies are concordant now that
emonstrate better biological efficacy of clopidogrel by
oubling the maintenance dose. Greater inhibition of plate-
et function with clopidogrel might also be associated with
educed ischemic events (10). However, the definite clinical
enefit of 150 mg/day clopidogrel has still to be demon-
trated in a large-scale clinical trial, and the ongoing
URRENT–OASIS 7 (Clopidogrel optimal loading dose
sage to Reduce Recurrent EveNTs–Optimal Antiplatelet
trategy for InterventionS) trial is addressing this issue.
lthough our study was not designed to measure clinical
utcomes, the lack of increased bleeding events, including
inor bleeding, in patients receiving 150 mg/day clopi-
ogrel for 1 month is reassuring data.
The second result of this study is the individual responsive-
ess to clopidogrel observed at 150 mg/day in patients catego-
ized as low responders at 75 mg/day. Indeed, each patient
howed a decrease in the PRI with the double dose of
lopidogrel, and 65% of this population reached values below
he threshold of 69%. These results, which agree with those of
Table 4. Correlation Between PRI 10 to 12 h After a 600-mg Clopidogrel
Loading Dose and the 75-mg/day Maintenance Dose at 2 Weeks
10–12 h PRI
Range, %
PRI at
2 Weeks, %
Nonresponders to
Clopidogrel 75 mg/day, %
Quartile 1 79.9–89.3 73.4 7.3 73
Quartile 2 74.1–79.4 68.6 11.9 67
Quartile 3 66.2–73.7 62.0 10.1 27
Quartile 4 18.6–65.9 41.7 18.1 18
Correlationbetweenplatelet reactivity index (PRI)measured10 to12hafter a 600-mgclopidogrel
loading dose and the patient response to the clopidogrel 75-mg/day maintenance dose at 2
weeks (n 45).ther studies, definitely demonstrate that “resistance” to clopi- cogrel can be overcome by dose titration. It should thus be
ossible to individually adapt the dosage on the basis of a
iological test (39). This of course raises the question of the
ppropriate test to perform and the appropriate threshold of
esponsiveness that should be reached (31,40).
At present, 3 tests to monitor thienopyridine therapy are
idely used in published reports: light transmission aggre-
ometry, the VerifyNow P2Y12 assay, and the VASP assay.
he clinical usefulness of light transmission aggregometry
n monitoring antiplatelet therapy is limited by the need for
large sample volume, complexity of sample preparation,
igh level of expertise required, time-consuming protocols,
igh cost, and variability of results from different laborato-
ies. The VerifyNow assay is based on platelet aggregation,
ith the great advantage of being semiautomated, cali-
rated, and standardized. The VASP assay is P2Y12-
elective and very reproducible, and the use of the commer-
ially available kit reduces interlaboratory variability of
esults. These 3 methods are well correlated, but the VASP
ssay is yet recognized as the gold standard to monitor
hienopyridine therapy (34). The appropriate threshold is
lso a matter of debate, depending on the threshold of
iological efficacy (30) or on the threshold of clinical efficacy
31). Recently used to adapt the loading dose before PCI
39), the VASP assay seems perhaps more suited to adapt
he maintenance dose that is less “aggressive” than the
oading dose and is not performed during the acute phase of
he coronary syndrome.
Multivariate analysis confirmed the significant effect of
he double maintenance dose of clopidogrel on the decrease
n PRI. However, body weight was also found to have a
ignificant effect on the PRI. Thus, patients with a high
ody weight presented with a high PRI regardless of the
aintenance dose. This observation is in agreement with
he observations of Feher et al. (41), who described more
ffective platelet inhibition with clopidogrel in patients
resenting with a lower body mass index, and the observa-
ion in the TRITON study, in which the authors suggested
greater bleeding risk with prasugrel in low body weight
atients (23).
Similarly, concomitant medication with a PPI tends to
ncrease the PRI, which fits in with the findings of Gilard et
l. (17), who reported that concomitant administration of
meprazole decreases the biological efficacy of clopidogrel as
easured by the VASP method. The clinical impact of body
eight or the concomitant use of a PPI on the individual
esponsiveness to clopidogrel must be confirmed by large-
cale trials before generating recommendations such as the
ystematic doubling the maintenance dose of clopidogrel in
hese cases. However, other predictors might have not been
dentified in our analysis because of insufficient statistical
ower, but this was not the aim of our study.
tudy limitations. Three limitations must be mentioned
oncerning this study. First, the sample size lacked statisti-
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637al power to measure a clinical benefit of the increased
aintenance dose of clopidogrel. This study was designed
nly to demonstrate a biological benefit of a higher dose of
lopidogrel. Although it is known that patients with suffi-
ient response to clopidogrel are at weak risk of cardiovas-
ular events (10), studies demonstrating improvement of
linical outcomes with clopidogrel at 150 mg/day are still
equired.
Second, the study did not include a control group of
nonresponders” who were maintained on clopidogrel 75
g/day (for comparison with nonresponders whose main-
enance dose was increased from 75 to 150 mg/day).
owever, the study was originally designed to see whether
hanging the dose could overcome poor responsiveness,
hich we show here. However, there is remarkable stability
f the PRI at 2 weeks in the individuals in whom the dose
f clopidogrel was maintained.
Finally, this was an open study, and a double-blind
esign was not used. However, the main criterion was a
iological parameter using a standardized assay, and the
echnicians performing the platelet function assays were
naware of the maintenance clopidogrel dose that each
atient had received.
onclusions
ur study demonstrates that the 150-mg/day maintenance
ose clopidogrel, compared with 75 mg/day, results in a
tronger inhibition of the platelet reactivity index measured
y the VASP phosphorylation assay. In addition, increasing
he maintenance dose to 150 mg/day could overcome low
esponsiveness to the standard maintenance dose of clopi-
ogrel. The clinical efficacy and the safety of the 150-mg/
ay maintenance dose remain to be demonstrated in large-
cale clinical trials.
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